Bespoke Circulating Tumor DNA Testing for Diagnostic Resolution, Disease Surveillance, and Treatment Monitoring in Hepatopancreatobiliary Malignancies: A Real-World Experience
Oluseyi Abidoye(Mayo Clinic), M. Borad(Mayo Clinic Hospital), Natalie Elliott(Mayo Clinic in Arizona), Christina Wu(Mayo Clinic Hospital), Mohamad Bassam Sonbol(WinnMed), Daniel H. Ahn(Mayo Clinic Hospital), Naohiro Okano(Kyorin University), Tanios Bekaii‐Saab(WinnMed), Kylee Andrews(Mayo Clinic Hospital), Angelo Pirozzi(Mayo Clinic Hospital), Bianca Urquieta(Mayo Clinic Hospital), Kelley Rone(Mayo Clinic Hospital), Edilia Guzman(Mayo Clinic Hospital), Elizabeth A. Raupach(Translational Genomics Research Institute)
Cited by 1
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
|British Journal of Cancer|2019|409